Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737990) titled 'Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression' on July 27.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Joshua Rosenblat

Condition: Treatment-resistant Depression (TRD)

Intervention: Other: Group integration therapy

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: July 1, 2026

Target Sample Size: 65

Countries of Recruitment: Canada

To know more, visit https://clinicaltrials.gov/study/NCT07737990

Disclaimer: Curate...